131675-32-6

Upstream product

• 4033-88-9 2-(4-nitrophenyl)malonic acid dimethyl ester 
• 74-88-4 methyl iodide 
• 108-59-8 malonic acid dimethyl ester 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 1402581-64-9 1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)-2H-pyrazol-3-yl]methyl]-3-[4-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]phenyl]urea 
• 1402581-66-1 1-[[5-tert-butyl-2-(3-chlorophenyl)-2H-pyrazol-3-yl]methyl]-3-[4-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]phenyl]urea 
• 29740-75-8 2-methyl-2-(4-nitrophenyl)propane-1,3-diol 
• 1236061-26-9 2-(4-aminophenyl)-2-methylpropane-1,3-diol 
• 1402585-95-8 phenyl 4-(1,3-dihydroxy-2-methylpropan-2-yl)phenylcarbamate 

Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN O-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives of formula (Q) as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use

This invention relates to arylaminoaryl-alkyl-substituted imidazolidone-2,4-diones of formula (I) and also to their physiologically tolerated salts: Wherein R, R′, R1 to R10, A, D, E, G, L and p are as defined herein. The invention also relates to processes for preparing them, pharmaceutical compositions comprising them and their therapeutic use. The compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.